Alterations in metabolism-related genes, such as IDH1 mutation, O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation, or epidermal growth factor receptor (EGFR) amplification, are frequent in glioma patients and are closely related to prognosis (12–15). This evidence concerns the gene IDH1 and central nervous system cancer.